In-depth coverage of specialist medicine
Adding chemotherapy to oral osimertinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer prolongs progression-free survival by up to nine months,…
Prophylactic bilateral salpingo-oophorectomy should be offered at time of obstetric-indicated caesarean delivery in women with the BRCA1 or BRCA2 pathogenic variants, say UK gynaecologists. In…
Fortnightly dupilumab with standard therapy leads to rapid and sustained improvements in asthma control for 6-11 year-olds with moderate to severe type 2 asthma, research…
On Wednesday, hundreds of Australian and overseas doctors will attend the opening of the Clinical Oncology Society of Australia’s 50th Annual Scientific Meeting in Melbourne.…
Corticosteroids and beta2 agonists are safe to use during pregnancy to manage asthma, say Japanese researchers who found no major impact of anti-asthmatic exposure on…
Perioperative durvalumab in combination with chemotherapy should be considered as a potential new treatment option for resectable non-small cell lung cancer, according to US oncologists.…
Progression-free survival is a poor surrogate for overall survival and should not be relied upon as a primary endpoint for registration and marketing of anticancer…
One in three adults with NAFLD-related cirrhosis and diabetes in the decade up to 2018 progressed to decompensated cirrhosis, an Australian study shows. Age, hypertension and extrahepatic cancer all…
Over-80s with colorectal cancer are far less likely to receive adjuvant chemotherapy than younger patients despite having similar oncological and post-resection outcomes, Australian doctors say. Their…
Prophylactic salpingo-oophorectomy at the time of breast cancer surgery in patients with the BRCA1 and BRCA2 pathogenic variants cuts the long-term risk of death by…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
